Skip to main content
Premium Trial:

Request an Annual Quote

Study Suggests Biodesix's Veristrat Can Identify NSCLC Responders to Erlotinib, Gemcitabine

Premium

Biodesix said this week that data from an analysis of serum and plasma samples from a Phase II non-small cell lung cancer study demonstrate that its Veristrat test is able to identify patients likely to benefit when treated with erlotinib – marketed by Roche as Tarceva – and erlotinib combined with gemcitabine.

The results were presented this week at the Chicago Multidisciplinary Symposia in Thoracic Oncology by Thomas Stinchcombe, associate professor of hematology/oncology at the University of North Carolina Lineberger Comprehensive Cancer Center.

In the study, which looked at 105 elderly advanced NSCLC patients, those identified as Veristrat "good" had statistically significant improvements in progression-free survival and overall survival compared to those classified as Veristrat "poor" when treated with erlotinib. Veristrat "good" patients also showed better PFS and OS compared to "poor" patients when treated with erlotinib combined with gemcitabine.

The study showed no significant difference between Veristrat "good" and "poor" patients treated with gemcitabine alone.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.